Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2215 vs salvage chemotherapy in relapsed/refractory FLT3-mutated AML
CTR20170326Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Started Aug 2017; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20170326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170326.